Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

DOI record: { "DOI": "10.1038/s41408-020-00372-5", "ISSN": [ "2044-5385" ], "URL": "http://dx.doi.org/10.1038/s41408-020-00372-5", "abstract": "<jats:title>Abstract</jats:title><jats:p>There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged &gt;65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.</jats:p>", "alternative-id": [ "372" ], "article-number": "103", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "31 July 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "6 August 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "6 August 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "19 October 2020" }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "M.-V.M. has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seatle Genetics, Pfizer, and Regeneron. J.M.-L. has received honoraria for participation in advisory boards from Novartis, Roche, BMS, Adaptive, Incyte, Amgen, and Janssen-Cilag. J.S.-M. has received honoraria for lectures and advisory boards from Amgen, Bristol–Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, and Roche. J.B. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. J.J.L. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, and Takeda. A.L. has received honoraria for advisory boards from Celgene, Amgen, and Janssen. P.M.-B. has received honoraria for advisory boards from Amgen. A.S. has received honoraria for advisory boards from Takeda, BMS, MSD, Sanofi, Roche, Novartis, Janssen, and Sandoz, and for a consultancy from Takeda, BMS, Novartis, Celgene, Janssen, Gilead, and Sanofi, and has received honoraria as a member of a Speakers Bureau for Takeda. F.E. has received honoraria for advisory boards from Celgene and Amgen. E.P.P. has received honoraria for advisory boards from Amgen and for lectures from BMS/Celgene and Janssen. C.F.d.L. has received honoraria for advisory boards from BMS/Celgene, Amgen, Takeda, and Janssen. L.F.C. reports honoraria for lectures from and membership on advisory boards with Celgene, Janssen, Roche, Novartis, Bristol–Myers Squibb, Amgen, Takeda, Pfizer, Incyte, and AbbVie. The remaining authors declare that they have no conflict of interest." } ], "author": [ { "ORCID": "http://orcid.org/0000-0001-7908-0063", "affiliation": [], "authenticated-orcid": false, "family": "Martínez-López", "given": "Joaquín", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0003-2390-1218", "affiliation": [], "authenticated-orcid": false, "family": "Mateos", "given": "María-Victoria", "sequence": "additional" }, { "affiliation": [], "family": "Encinas", "given": "Cristina", "sequence": "additional" }, { "affiliation": [], "family": "Sureda", "given": "Anna", "sequence": "additional" }, { "affiliation": [], "family": "Hernández-Rivas", "given": "José Ángel", "sequence": "additional" }, { "affiliation": [], "family": "Lopez de la Guía", "given": "Ana", "sequence": "additional" }, { "affiliation": [], "family": "Conde", "given": "Diego", "sequence": "additional" }, { "affiliation": [], "family": "Krsnik", "given": "Isabel", "sequence": "additional" }, { "affiliation": [], "family": "Prieto", "given": "Elena", "sequence": "additional" }, { "affiliation": [], "family": "Riaza Grau", "given": "Rosalía", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-8106-8909", "affiliation": [], "authenticated-orcid": false, "family": "Gironella", "given": "Mercedes", "sequence": "additional" }, { "affiliation": [], "family": "Blanchard", "given": "María Jesús", "sequence": "additional" }, { "affiliation": [], "family": "Caminos", "given": "Nerea", "sequence": "additional" }, { "affiliation": [], "family": "Fernández de Larrea", "given": "Carlos", "sequence": "additional" }, { "affiliation": [], "family": "Senin", "given": "María Alicia", "sequence": "additional" }, { "affiliation": [], "family": "Escalante", "given": "Fernando", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2563-7510", "affiliation": [], "authenticated-orcid": false, "family": "de la Puerta", "given": "José Enrique", "sequence": "additional" }, { "affiliation": [], "family": "Giménez", "given": "Eugenio", "sequence": "additional" }, { "affiliation": [], "family": "Martínez-Barranco", "given": "Pilar", "sequence": "additional" }, { "affiliation": [], "family": "Mateos", "given": "Juan José", "sequence": "additional" }, { "affiliation": [], "family": "Casado", "given": "Luis Felipe", "sequence": "additional" }, { "affiliation": [], "family": "Bladé", "given": "Joan", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3393-9570", "affiliation": [], "authenticated-orcid": false, "family": "Lahuerta", "given": "Juan José", "sequence": "additional" }, { "affiliation": [], "family": "de la Cruz", "given": "Javier", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9183-4857", "affiliation": [], "authenticated-orcid": false, "family": "San-Miguel", "given": "Jesús", "sequence": "additional" } ], "container-title": "Blood Cancer Journal", "container-title-short": "Blood Cancer J.", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 10, 19 ] ], "date-time": "2020-10-19T14:07:20Z", "timestamp": 1603116440000 }, "deposited": { "date-parts": [ [ 2022, 12, 5 ] ], "date-time": "2022-12-05T14:35:57Z", "timestamp": 1670250957000 }, "indexed": { "date-parts": [ [ 2024, 3, 20 ] ], "date-time": "2024-03-20T00:36:53Z", "timestamp": 1710895013667 }, "is-referenced-by-count": 53, "issue": "10", "issued": { "date-parts": [ [ 2020, 10, 19 ] ] }, "journal-issue": { "issue": "10", "published-online": { "date-parts": [ [ 2020, 10 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 19 ] ], "date-time": "2020-10-19T00:00:00Z", "timestamp": 1603065600000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 19 ] ], "date-time": "2020-10-19T00:00:00Z", "timestamp": 1603065600000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41408-020-00372-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41408-020-00372-5", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41408-020-00372-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2020, 10, 19 ] ] }, "published-online": { "date-parts": [ [ 2020, 10, 19 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "372_CR1", "unstructured": "World Health Organization. Novel Coronavirus–China. World Health Organization. https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china (WHO, 2020)." }, { "DOI": "10.1016/S0140-6736(20)30566-3", "author": "F Zhou", "doi-asserted-by": "publisher", "first-page": "1054", "journal-title": "Lancet", "key": "372_CR2", "unstructured": "Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.1001/jamainternmed.2020.0994", "author": "C Wu", "doi-asserted-by": "publisher", "first-page": "934", "journal-title": "JAMA Intern. Med", "key": "372_CR3", "unstructured": "Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934–943 (2020).", "volume": "180", "year": "2020" }, { "DOI": "10.1056/NEJMoa2002032", "author": "W-J Guan", "doi-asserted-by": "publisher", "first-page": "1708", "journal-title": "N. Engl. J. Med.", "key": "372_CR4", "unstructured": "Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.03.296", "author": "L Zhang", "doi-asserted-by": "publisher", "first-page": "894", "journal-title": "Ann. Oncol.", "key": "372_CR5", "unstructured": "Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 31, 894–901 (2020).", "volume": "31", "year": "2020" }, { "DOI": "10.1016/S1470-2045(20)30096-6", "author": "W Liang", "doi-asserted-by": "publisher", "first-page": "335", "journal-title": "Lancet Oncol.", "key": "372_CR6", "unstructured": "Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020).", "volume": "21", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31173-9", "author": "LYW Lee", "doi-asserted-by": "publisher", "first-page": "1919", "journal-title": "Lancet", "key": "372_CR7", "unstructured": "Lee, L. Y. W. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395, 1919–1926 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.3324/haematol.2014.107714", "author": "C Blimark", "doi-asserted-by": "publisher", "first-page": "107", "journal-title": "Haematologica", "key": "372_CR8", "unstructured": "Blimark, C. et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100, 107–113 (2015).", "volume": "100", "year": "2015" }, { "DOI": "10.4049/jimmunol.0901596", "author": "M Basler", "doi-asserted-by": "publisher", "first-page": "6145", "journal-title": "J. Immunol.", "key": "372_CR9", "unstructured": "Basler, M., Lauer, C., Beck, U. & Groettrup, M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 183, 6145–6150 (2009).", "volume": "183", "year": "2009" }, { "DOI": "10.1007/s00277-018-3284-y", "author": "M Chen", "doi-asserted-by": "publisher", "first-page": "925", "journal-title": "Ann. Hematol.", "key": "372_CR10", "unstructured": "Chen, M. et al. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann. Hematol. 97, 925–944 (2018).", "volume": "97", "year": "2018" }, { "DOI": "10.1158/1078-0432.CCR-16-3192", "author": "X Feng", "doi-asserted-by": "publisher", "first-page": "4290", "journal-title": "Clin. Cancer Res.", "key": "372_CR11", "unstructured": "Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290–4300 (2017).", "volume": "23", "year": "2017" }, { "DOI": "10.1371/journal.pone.0211927", "author": "H Nahi", "doi-asserted-by": "publisher", "journal-title": "PLoS ONE", "key": "372_CR12", "unstructured": "Nahi, H. et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS ONE 14, e0211927 (2019).", "volume": "14", "year": "2019" }, { "DOI": "10.1182/bloodadvances.2020001907", "author": "X Zhang", "doi-asserted-by": "publisher", "first-page": "1307", "journal-title": "Blood Adv.", "key": "372_CR13", "unstructured": "Zhang, X. et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 4, 1307–1310 (2020).", "volume": "4", "year": "2020" }, { "DOI": "10.1111/bjh.16874", "doi-asserted-by": "publisher", "key": "372_CR14", "unstructured": "Cook, G. et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br. J. Haematol. https://doi.org/10.1111/bjh.16874 (2020)." }, { "DOI": "10.1038/s41375-41020-40876-z", "doi-asserted-by": "publisher", "key": "372_CR15", "unstructured": "Terpos, E. et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. https://doi.org/10.1038/s41375-41020-40876-z (2020)." }, { "DOI": "10.1111/imj.14859", "doi-asserted-by": "publisher", "key": "372_CR16", "unstructured": "Di Ciaccio, P. et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern. Med. J. https://doi.org/10.1111/imj.14859 (2020)." }, { "DOI": "10.1016/j.htct.2020.1005.1001", "doi-asserted-by": "publisher", "key": "372_CR17", "unstructured": "Hungria, V. et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel—ABHH Monoclonal Gammopathies Committe. Hematol. Transfus Cell Ther. https://doi.org/10.1016/j.htct.2020.1005.1001 (2020)." }, { "DOI": "10.1016/j.jgo.2020.04.008", "author": "H Mian", "doi-asserted-by": "publisher", "first-page": "764", "journal-title": "J. Geriatr. Oncol.", "key": "372_CR18", "unstructured": "Mian, H. et al. Caring for older adults with multiple myeloma during the COVID-19 pandemic: perspective from the international forum for optimizing care of older adults with myeloma. J. Geriatr. Oncol. 11, 764–768 (2020).", "volume": "11", "year": "2020" }, { "DOI": "10.1159/000507690", "doi-asserted-by": "publisher", "key": "372_CR19", "unstructured": "Al Saleh, A. S., Sher, T. & Gertz, M. A. Multiple myeloma in the time of COVID-19. Acta Haematol. https://doi.org/10.1159/000507690 (2020)." }, { "DOI": "10.3324/haematol.2011.044933", "author": "E Barragan", "doi-asserted-by": "publisher", "first-page": "1470", "journal-title": "Haematologica", "key": "372_CR20", "unstructured": "Barragan, E. et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica 96, 1470–1477 (2011).", "volume": "96", "year": "2011" }, { "DOI": "10.7326/M14-0698", "author": "KG Moons", "doi-asserted-by": "publisher", "first-page": "W1", "journal-title": "Ann. Intern. Med.", "key": "372_CR21", "unstructured": "Moons, K. G. et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 162, W1–W73 (2015).", "volume": "162", "year": "2015" }, { "DOI": "10.1093/jnci/djy088", "author": "W Sauerbrei", "doi-asserted-by": "publisher", "first-page": "803", "journal-title": "J. Natl Cancer Inst.", "key": "372_CR22", "unstructured": "Sauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M. & Altman, D. G. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J. Natl Cancer Inst. 110, 803–811 (2018).", "volume": "110", "year": "2018" }, { "DOI": "10.7326/0003-4819-158-4-201302190-00009", "author": "JA Hayden", "doi-asserted-by": "publisher", "first-page": "280", "journal-title": "Ann. Intern. Med.", "key": "372_CR23", "unstructured": "Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P. & Bombardier, C. Assessing bias in studies of prognostic factors. Ann. Intern. Med. 158, 280–286 (2013).", "volume": "158", "year": "2013" }, { "DOI": "10.1056/NEJMoa2004500", "author": "PK Bhatraju", "doi-asserted-by": "publisher", "first-page": "2012", "journal-title": "N. Engl. J. Med.", "key": "372_CR24", "unstructured": "Bhatraju, P. K. et al. Covid-19 in critically Ill patients in the Seattle region—case series. N. Engl. J. Med. 382, 2012–2022 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1001/jama.2020.4031", "doi-asserted-by": "publisher", "key": "372_CR25", "unstructured": "Grasselli, G., Pesenti, A. & Cecconi, M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.4031 (2020)." }, { "DOI": "10.1111/bjh.16801", "doi-asserted-by": "publisher", "key": "372_CR26", "unstructured": "Martín-Moro, F. et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br. J. Haematol. https://doi.org/10.1111/bjh.16801 (2020)." }, { "DOI": "10.1111/ajt.15929", "doi-asserted-by": "publisher", "key": "372_CR27", "unstructured": "Fernández-Ruiz, M. et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am. J. Transplant. https://doi.org/10.1111/ajt.15929 (2020)." }, { "DOI": "10.1016/j.kint.2020.03.005", "author": "Y Cheng", "doi-asserted-by": "publisher", "first-page": "829", "journal-title": "Kidney Int.", "key": "372_CR28", "unstructured": "Cheng, Y. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 97, 829–838 (2020).", "volume": "97", "year": "2020" } ], "reference-count": 28, "references-count": 28, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.1101/2020.06.29.20142455", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41408-020-00372-5" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Oncology", "Hematology" ], "subtitle": [], "title": "Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "10" }